Effect of Dairy Consumption and Its Fat Content on Glycemic Control and Cardiovascular Risk Factors in Patients with Type 2 Diabetes—A Randomized Controlled Study
| Autor: | Shaheen Tomah, Veronica Salsberg, Osama Hamdy, Khaled Alsibai, Taha Elseaidy, Joanna Mitri, Noor Mahmoud, Adham Mottalib, Sahar Ashrafzadeh |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Calorie medicine.diagnostic_test business.industry Endocrinology Diabetes and Metabolism Saturated fat Type 2 diabetes medicine.disease law.invention 03 medical and health sciences 0302 clinical medicine Blood pressure Randomized controlled trial law Spouse Internal medicine Internal Medicine medicine 030212 general & internal medicine business Lipid profile 030217 neurology & neurosurgery Glycemic |
| Zdroj: | Diabetes. 67 |
| ISSN: | 1939-327X 0012-1797 |
| DOI: | 10.2337/db18-760-p |
| Popis: | The 2015 Dietary Guidelines for Americans recommend daily consumption of 3 servings of low or non-fat dairy. However, the effects of dairy consumption and its fat content on glycemic control and cardiovascular risk factors in patients with type 2 diabetes (T2D) are unknown. This study was designed to evaluate the impact of higher consumption of full-fat and low/non-fat dairy on HbA1c, lipid profile and blood pressure (BP) in patients with T2D. We enrolled 72 participants with uncontrolled T2D (mean age 59±8 years, 46% females) who were consuming At baseline, mean T2D duration was 14±8 years, HbA1c 8.1±1.0%, body weight 92±17 kg, daily caloric intake 1885±600 kcal (43.4±7.0% carbohydrates, 37.8±5.5% fat, 13.0±2.8% saturated fat, and 18.1±3.6% protein), LDL-C 80±26 mg/dL, HDL-C 47±16 mg/dL, triglycerides 172±178 mg/dL, systolic BP 129±16 mmHg and diastolic BP 72±8 mmHg. There were no differences between groups in any of these parameters at baseline. At 6 months, percent calories from saturated fat increased by 3.7±0.8% in group A (p This study shows that increasing consumption of dairy products to ≥3 servings/day, irrespective of fat content, has no effect on HbA1c, lipid profile or BP in patients with T2D. Disclosure A. Mottalib: None. J. Mitri: Research Support; Self; National Dairy Council, Kowa Pharmaceuticals America, Inc.. Research Support; Spouse/Partner; AbbVie Inc., Janssen Pharmaceuticals, Inc., Takeda Pharmaceuticals U.S.A., Inc., Gilead Sciences, Inc.. Consultant; Spouse/Partner; Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Biogen, AbbVie Inc.. V. Salsberg: None. S. Ashrafzadeh: None. T. Elseaidy: None. S. Tomah: None. K. Alsibai: None. N. Mahmoud: None. O. Hamdy: Research Support; Self; Abbott. Advisory Panel; Self; AstraZeneca. Consultant; Self; Merck & Co., Inc.. Research Support; Self; Novo Nordisk A/S. Stock/Shareholder; Self; Healthimation, LLC.. Consultant; Self; Sanofi-Aventis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|